Managing Cardiovascular Disease Through Cholesterol Reduction.

Patients with cardiovascular diseases often have much higher LDL cholesterol levels than recommended in the guidelines, and only a minority of patients receive combination therapy, and PCSK9 inhibitors are rarely prescribed. The recent SANTORINI study once again highlights the need for the intensive application of lipid-lowering drugs. The DA-VINCI study showed a massive discrepancy between the target levels of LDL cholesterol stipulated in the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines and the levels achieved in clinical practice.